Ann Arbor, Mich.
Went public 8/10/2000 at $9 per share
Filing Range: 6 mil. shares @ $8 to $10
Shares Outstanding: 24 mil. shares
Underwriters: Roberston Stephens & Co./Chase H&Q/U.S. Bancorp Piper
Jaffray
Company Counsel: Morgan Lewis & Bockius
Manager Counsel: Testa Hurwitz & Thibeault
Auditor: Arthur Andersen & Co.
The Company:
Develops therapeutics for patients with atherosclerosis and related metabolic disorders. The company focuses on discovering new therapies in hope of treating metabolic diseases like strokes, obesity, diabetes and Alzheimer’s.
Venture Backers:
TL Ventures
Oak Investment Partners
Canaan Partners
Avalon Investments Inc.
Scheer & Co.
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 07/01/19983 Early Stage500.0
2 08/12/19984 Early Stage14500.0
3 01/18/20007 Expansion 21425.0
4 02/08/20001 Later Stage5000.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $0.0
Net Income: -10.7